on SANOFI-AVENTIS (EPA:SAN)
Sanofi-Teva: Duvakitug Promises for Inflammatory Bowel Diseases
The RELIEVE UCCD study uncovers the potential of duvakitug, a monoclonal antibody targeting TL1A, to treat moderate to severe ulcerative colitis and Crohn’s disease. Presented at ECCO 2025, these data show encouraging efficacy and safety.
In patients with ulcerative colitis, significant clinical remissions were observed with duvakitug, surpassing placebo. Similarly, for Crohn's disease, endoscopic responses indicate a promising development.
The launch of a phase III program is planned for 2025, underlining the ambition of Sanofi and Teva in this field. Although well tolerated, duvakitug is still awaiting regulatory approval. This collaboration between the two companies could open new therapeutic options for patients in dire need of solutions.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SANOFI-AVENTIS news